gila monster and glp-1 The system that turned venom into drugs is now being dismantled through budget cuts for scientific research, Jeff Coller writes. “Less support for scientists means strange questions no one The Gila Monster Venom Lead

GLP-1 RA-mediated gastric slowing delays levothyroxine transit into the duodenum, potentially reducing peak absorption

the Judicial Panel on Multidistrict Litigation added Saxenda to MDL 3094 in December 2024, expanding the scope to include this earlier-generation GLP-1 medication The consolidation of these medications into a single MDL proceedings streamlines the litigation process while allowing each plaintiff to maintain their individual claim for damages

Disclaimer: Results not typical

Chromium picolinate adds a separately studied blood sugar signaling pathway

GLP-1 RAs exhibit anti-inflammatory properties through inhibition of NF-B pathways and macrophage infiltration in adipose tissue

The oral non-peptide GLP-1 receptor agonist market was dominated by North America in 2025 due to the high prevalence of obesity and diabetes, strong pharmaceutical research capabilities, and widespread adoption of innovative therapeutics